“…Stem-cell therapies were offered as a treatment option due to malignant diseases (leukemia, lymphoma, myelodysplastic syndrome, and pineoblastoma) in most cases and rarely due to autoimmune-mediated diseases (one each for MS, myelitis, and CIDP) [ 23 , 136 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 ]. Hematopoietic stem cells of different origin (allogeneic n = 26, autologous n = 1, and not described n = 1) were infused in all but two patients [ 23 , 136 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 ]. In these two patients, allogeneic umbilical cord blood-derived mesenchymal stem cells and autologous bone marrow-derived mesenchymal stem cells (myelitis) were applied for the treatment of autoimmune-mediated diseases [ 189 , 190 ].…”